Physician profile
Andrew J Miller
NPI 1134133945
$4,506.11
in general payments reported to CMS, 2019-2025
11 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Plastic Surgery Within The Head and Neck provider received nationally (typical 2025 total: $300).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,409 · 2020: $37.66 · 2021: $40.37 · 2022: $121 · 2023: $353 · 2024: $311 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,273.65 | 2019-2022 | |
| Abbvie INC. | $385.83 | 2023-2025 | |
| Merz North America, INC. | $368.96 | 2019-2023 | Xeomin |
| Genzyme Corporation | $144.51 | 2022-2023 | |
| Smith+Nephew, INC. | $133.86 | 2024 | Trigen Intertan |
| Convatec INC. | $56.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $50.65 | 2023-2024 | Nucala |
| Musculoskeletal Transplant Foundation INC. | $34.99 | 2023 | |
| Galderma Laboratories, L.P. | $30.04 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2023 | Seglentis |
| Alcon Vision LLC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.